title: Biliary excretion of rufloxacin in humans.
abstract: Rufloxacin is a new once-daily antibacterial fluoroquinolone with a long half-life. The aim of the present study was to evaluate the plasma and biliary kinetics and biliary and urinary excretion of rufloxacin in patients with extrahepatic cholestasis. Twelve patients with total external percutaneous transhepatic biliary drainage were given a single oral dose of 400 mg of rufloxacin. Plasma, bile, and urine samples and fractions were collected over 72 h after drug administration. Rufloxacin and its major metabolite, the N-desmethyl derivative, were measured by high-performance liquid chromatography. Maximum rufloxacin concentrations in plasma and bile (means +/- standard deviations) were 4.05 +/- 1.38 micrograms/ml and 8.24 +/- 7.16 micrograms/ml, respectively, and were reached in 4.2 +/- 3.0 h and 4.2 +/- 3.5 h, respectively. The terminal elimination half-life of rufloxacin in plasma was 45.1 +/- 13.5 h. Apparent plasma clearance was 31.3 +/- 10.5 ml/min, while biliary clearance was 0.4 +/- 0.2 ml/min and renal clearance was 12.7 +/- 6.0 ml/min. In 72 h, 0.9% +/- 0.8% of the dose given was recovered in bile and 27.2% +/- 12.0% was recovered in urine. Biliary concentrations exceeded the MICs of most common biliary tract pathogens for at least 24 h after administration. The broad antibacterial spectrum of rufloxacin and its high and prolonged biliary concentrations suggest that this drug may be useful for treatment of biliary tract infections.
authors.affiliation: Institute of Hygiene, University of Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Privitera
authors.forename: G
authors.initials: G
authors.lastname: Nicastro
authors.forename: B P
authors.initials: BP
authors.lastname: Imbimbo
authors.forename: M
authors.initials: M
authors.lastname: Cesana
authors.forename: M
authors.initials: M
authors.lastname: Visconti
authors.forename: F
authors.initials: F
authors.lastname: Lombardi
authors.forename: G
authors.initials: G
authors.lastname: Tagliabue
authors.forename: E
authors.initials: E
authors.lastname: Faleschini
authors.forename: F
authors.initials: F
authors.lastname: Colturani
authors.forename: P
authors.initials: P
authors.lastname: Franzini
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000890:Anti-Infective Agents / Q000493:pharmacokinetics*; D001646:Bile / Q000378:metabolism / Q000502:physiology; D001659:Biliary Tract / Q000378:metabolism*; D001651:Cholestasis, Extrahepatic / Q000378:metabolism*; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D015363:Quinolones / Q000493:pharmacokinetics*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C060328:rufloxacin